Latest news with #Guggenheim
Reuters
2 hours ago
- Business
- Reuters
Novo Nordisk slides further on US competition, new CEO concerns
COPENHAGEN, July 30 (Reuters) - Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs in the United States, a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value. Novo Nordisk slashed its outlook for 2025 sales growth on Tuesday and said it had appointed veteran insider Maziar Mike Doustdar as its new CEO, tasked with reviving its performance in the United States, the largest market for weight-loss drugs. Novo said the lower sales outlook reflected competition from "compounded" copycats to Wegovy, custom-made medicines that are based on the same ingredients as branded drugs, which took investors by surprise. While Novo said it was intensifying its efforts to regain patients taking copycat drugs and limit unlawful compounding, analysts at Guggenheim said Novo's new 2025 guidance did not assume compounding volumes coming down. Its shares closed down 23% on Tuesday after tumbling as much as 30%. On Wednesday, they had fallen a further 4.1% by 1257 GMT. Novo became Europe's most valuable listed company following the launch of Wegovy in 2021 but its shares have fallen by two-thirds since peaking in June last year on concerns the drugmaker is losing ground in the obesity drug race. Despite the problems, incoming CEO Doustdar said on an investor call on Tuesday that "we are having a fantastic growth right now with Wegovy". "This has really become a severe credibility issue," said Barclays analyst Emily Field. "They don't view the issues that they have as severely as the market does, and that's creating a big problem." Doustdar told investors a priority will be to move faster and improve "commercial execution" but did not reveal any new strategic direction. He currently heads all commercial units globally, minus the United States, which according to analysts at TD Cowen had been "a brighter spot in Novo's commercial efforts, which could help to buoy the current platform as the pipeline advances". Barclays downgraded the stock to "equal-weight" from "overweight". Bank of America also downgraded the stock to "neutral" from "buy".
Business Insider
10 hours ago
- Business
- Business Insider
Guggenheim Reaffirms Their Buy Rating on CommVault Systems (CVLT)
Guggenheim analyst Howard Ma maintained a Buy rating on CommVault Systems yesterday and set a price target of $220.00. The company's shares closed yesterday at $193.27. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Ma is a 4-star analyst with an average return of 13.2% and a 56.86% success rate. Ma covers the Technology sector, focusing on stocks such as CommVault Systems, MongoDB, and Elastic. In addition to Guggenheim, CommVault Systems also received a Buy from William Blair's Jason Ader in a report issued yesterday. However, on July 25, Cantor Fitzgerald reiterated a Hold rating on CommVault Systems (NASDAQ: CVLT). CVLT market cap is currently $7.28B and has a P/E ratio of 96.87. Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVLT in relation to earlier this year. Most recently, in May 2025, Sanjay Mirchandani, the President & CEO of CVLT sold 1,709.00 shares for a total of $299,075.00.
Condé Nast Traveler
a day ago
- Entertainment
- Condé Nast Traveler
The Best Hotels in Bilbao, Northern Spain's Cultural Capital
Looking out towards the Guggenheim's sweeping titanium and glass frame, The Artist is a luxurious spot for any traveler fascinated by design. Originally called the Gran Hotel Domine, The Artist opened in 2002 and was designed by Spanish artists and architects Javier Mariscal and Fernando Salas, while Jeff Koons' floral 40-foot sculpture Puppy sits just outside the entrance. The airy lobby is dominated by the towering Fossil Cypress, an 85-foot column of rolled stone designed by Marisco that awkwardly soars up to the seventh (and top) floor. Speaking of the summit, it's The Artist's rooftop bar—imaginatively titled The Rooftop—that's perhaps most impressive here. While the view of the Guggenheim is obviously the star, the eye is also drawn to the lush hills and the distant hillside neighborhoods of Bilbao's extraordinary cityscape. Soak up the panorama with Idiazabal cheese, Iberico ham, and a glass of fruit-forward Rioja Crianza. Quality downstairs restaurant Olio and secret lobby cocktail bar Sixty One 61 form a fine gastronomic triumvirate. The hotel boasts 145 rooms, most of which exude a warm palette with bright midcentury lounging chairs but are thankfully restrained on the art, which is left to the public spaces. The sublime 861-square-foot penthouse comes with its own private terrace facing the museum. And to unwind, the oak-wood Turkish bath and sauna are perfect escapes from an admittedly tourist-heavy corner of Bilbao.
Yahoo
a day ago
- Business
- Yahoo
New Drug, New Direction: J&J Moves Deeper Into Late-Stage Therapeutics
Johnson & Johnson (NYSE:JNJ) is one of the . On July 21, 2025, J&J submitted a New Drug Application to the U.S. FDA for icotrokinra, an oral peptide therapy targeting moderate to severe plaque psoriasis in patients aged 12 and older—signaling a strong late‑stage R&D pipeline with growth potential beyond consumer staples or medtech divisions. On the analyst front, Guggenheim recently raised its price target from $164 to $167, while holding a Neutral rating in mid‑July 2025. The modest upgrade shows confidence in J&J's strategic balance between innovation and defensive income streams. Emilio100 / Despite being broadly diversified across consumer health, pharmaceuticals, and medical devices, J&J is relatively insulated from trade‑war volatility. Its supply chains are diffuse, production is localized in multiple markets, and it sources materials from global partners across regions less exposed to high tariffs. That allows J&J to preserve margin power and delivery continuity across geopolitical shifts. Johnson & Johnson is a global healthcare conglomerate spanning pharmaceuticals, medical devices, and consumer health products. Known for its scale and scientific depth, it operates in over 60 countries. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales
Eli Lilly & Company (NYSE:LLY) ranks among the . On July 11, Guggenheim reiterated its Buy rating on Eli Lilly & Company (NYSE:LLY) ahead of the company's second-quarter earnings report and increased its price target from $936 to $942. Pixabay/Public Domain In contrast to the consensus predictions of $4.39 billion from VisibleAlpha and $4.89 billion from FactSet, the firm projects second-quarter Mounjaro sales of $4.49 billion. Guggenheim also predicts that Zepbound will rake in $3.10 billion in US sales in the second quarter, which is marginally more than the $2.94 billion consensus estimate. Guggenheim's modified model also takes into account a projected $0.14 effect on earnings per share from second-quarter IPR&D, as well as improved tirzepatide expectations based on prescription analysis. The firm also emphasized that investors are paying close attention to net price and prescription trends for tirzepatide, as well as a number of important clinical trial readouts scheduled through the end of 2025. Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world's largest pharmaceutical companies. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
